2025 Q2 -tulosraportti
220 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenAre there any exchanges that are open tomorrow?- ·1 t sittenSo now that it's also being written about in Germany, will there probably be many more stock buyers entering the market? This could easily both double and triple itself without news, it seems?
·2 t sittenThe code Big Pharma is missing – A reality check on the leadership and technology in Circio 🧬💼 Many on the forum focus exclusively on the daily fluctuations on the screen. In the short-term noise, it's easy to forget who is actually driving the company forward, and what they are really building. If we dig a little deeper into the foundation, a picture emerges of a team and a platform built to solve one of modern medicine's biggest bottlenecks: 1. The problem we solve (Why traditional mRNA is not enough) 📉 mRNA vaccines were a revolution, but traditional, linear mRNA has a fundamental weakness: It is fragile. The body's enzymes break it down in a few days. This means that if chronic diseases or cancer are to be treated, frequent, expensive, and burdensome dosages are required. It is neither scalable for the patient nor the healthcare system. The answer is circVec (circular RNA). By binding the RNA together in a circle without loose ends, it is protected against degradation. This means that the medicine can have an effect in the body over weeks and months. This is the next big upgrade Big Pharma is completely dependent on. To commercialize this, Circio has two key individuals who give the company unusually strong weight: 2. The Science: Dr. Thomas B. Hansen (CTO) 🔬 He is not just a skilled researcher; he is one of the global pioneers in circular RNA. In 2013, Hansen was the lead author of a groundbreaking study published in Nature (the world's foremost science journal), which helped kickstart global interest in the field. His research has been cited over 6,000 times. Circio has not just brought in expertise – they have the man who helped establish the foundation the rest of the world is now researching. 3. The Strategy: Dr. Erik Digman Wiklund (CEO) ♟️ Groundbreaking biotechnology often dies out because companies lack commercial acumen. Wiklund himself has a doctorate, but just as important is his background from McKinsey & Company, where he was a strategy consultant for Big Pharma specifically. He understands the inside of the giants we will negotiate with. He knows what they value, how they think about acquisitions, and he systematically positions the company to maximize the value of our technology before a potential partnership agreement. When the stock market opens again on Tuesday, there will undoubtedly be new volatility and noise from day traders. But for those of us who are able to zoom out: We own a technology that solves the healthcare system's big mRNA problem, led by a global science pioneer and a commercial strategist. Knowledge is the best medicine against market turmoil. Enjoy the rest of Easter, and know what you own. ☕️📈
·3 t sittenUnfortunately, I don't have any of this, but I have 50k ready to invest here at opening. FOMO, or not?
·3 t sittenDo you have other companies to recommend, which are also almost as good as this one?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
220 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenAre there any exchanges that are open tomorrow?
- ·1 t sittenSo now that it's also being written about in Germany, will there probably be many more stock buyers entering the market? This could easily both double and triple itself without news, it seems?
- ·2 t sittenThe code Big Pharma is missing – A reality check on the leadership and technology in Circio 🧬💼 Many on the forum focus exclusively on the daily fluctuations on the screen. In the short-term noise, it's easy to forget who is actually driving the company forward, and what they are really building. If we dig a little deeper into the foundation, a picture emerges of a team and a platform built to solve one of modern medicine's biggest bottlenecks: 1. The problem we solve (Why traditional mRNA is not enough) 📉 mRNA vaccines were a revolution, but traditional, linear mRNA has a fundamental weakness: It is fragile. The body's enzymes break it down in a few days. This means that if chronic diseases or cancer are to be treated, frequent, expensive, and burdensome dosages are required. It is neither scalable for the patient nor the healthcare system. The answer is circVec (circular RNA). By binding the RNA together in a circle without loose ends, it is protected against degradation. This means that the medicine can have an effect in the body over weeks and months. This is the next big upgrade Big Pharma is completely dependent on. To commercialize this, Circio has two key individuals who give the company unusually strong weight: 2. The Science: Dr. Thomas B. Hansen (CTO) 🔬 He is not just a skilled researcher; he is one of the global pioneers in circular RNA. In 2013, Hansen was the lead author of a groundbreaking study published in Nature (the world's foremost science journal), which helped kickstart global interest in the field. His research has been cited over 6,000 times. Circio has not just brought in expertise – they have the man who helped establish the foundation the rest of the world is now researching. 3. The Strategy: Dr. Erik Digman Wiklund (CEO) ♟️ Groundbreaking biotechnology often dies out because companies lack commercial acumen. Wiklund himself has a doctorate, but just as important is his background from McKinsey & Company, where he was a strategy consultant for Big Pharma specifically. He understands the inside of the giants we will negotiate with. He knows what they value, how they think about acquisitions, and he systematically positions the company to maximize the value of our technology before a potential partnership agreement. When the stock market opens again on Tuesday, there will undoubtedly be new volatility and noise from day traders. But for those of us who are able to zoom out: We own a technology that solves the healthcare system's big mRNA problem, led by a global science pioneer and a commercial strategist. Knowledge is the best medicine against market turmoil. Enjoy the rest of Easter, and know what you own. ☕️📈
- ·3 t sittenUnfortunately, I don't have any of this, but I have 50k ready to invest here at opening. FOMO, or not?
- ·3 t sittenDo you have other companies to recommend, which are also almost as good as this one?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
220 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenAre there any exchanges that are open tomorrow?
- ·1 t sittenSo now that it's also being written about in Germany, will there probably be many more stock buyers entering the market? This could easily both double and triple itself without news, it seems?
- ·2 t sittenThe code Big Pharma is missing – A reality check on the leadership and technology in Circio 🧬💼 Many on the forum focus exclusively on the daily fluctuations on the screen. In the short-term noise, it's easy to forget who is actually driving the company forward, and what they are really building. If we dig a little deeper into the foundation, a picture emerges of a team and a platform built to solve one of modern medicine's biggest bottlenecks: 1. The problem we solve (Why traditional mRNA is not enough) 📉 mRNA vaccines were a revolution, but traditional, linear mRNA has a fundamental weakness: It is fragile. The body's enzymes break it down in a few days. This means that if chronic diseases or cancer are to be treated, frequent, expensive, and burdensome dosages are required. It is neither scalable for the patient nor the healthcare system. The answer is circVec (circular RNA). By binding the RNA together in a circle without loose ends, it is protected against degradation. This means that the medicine can have an effect in the body over weeks and months. This is the next big upgrade Big Pharma is completely dependent on. To commercialize this, Circio has two key individuals who give the company unusually strong weight: 2. The Science: Dr. Thomas B. Hansen (CTO) 🔬 He is not just a skilled researcher; he is one of the global pioneers in circular RNA. In 2013, Hansen was the lead author of a groundbreaking study published in Nature (the world's foremost science journal), which helped kickstart global interest in the field. His research has been cited over 6,000 times. Circio has not just brought in expertise – they have the man who helped establish the foundation the rest of the world is now researching. 3. The Strategy: Dr. Erik Digman Wiklund (CEO) ♟️ Groundbreaking biotechnology often dies out because companies lack commercial acumen. Wiklund himself has a doctorate, but just as important is his background from McKinsey & Company, where he was a strategy consultant for Big Pharma specifically. He understands the inside of the giants we will negotiate with. He knows what they value, how they think about acquisitions, and he systematically positions the company to maximize the value of our technology before a potential partnership agreement. When the stock market opens again on Tuesday, there will undoubtedly be new volatility and noise from day traders. But for those of us who are able to zoom out: We own a technology that solves the healthcare system's big mRNA problem, led by a global science pioneer and a commercial strategist. Knowledge is the best medicine against market turmoil. Enjoy the rest of Easter, and know what you own. ☕️📈
- ·3 t sittenUnfortunately, I don't have any of this, but I have 50k ready to invest here at opening. FOMO, or not?
- ·3 t sittenDo you have other companies to recommend, which are also almost as good as this one?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt